Cost Analysis: Port Delivery System versus Monthly Ranibizumab for Wet Age-Related Macular Degeneration Treatment

被引：3

作者：

Al-Khersan, Hasenin ^{[1
]}

Patel, Nimesh A. ^{[2
,3
]}

Yannuzzi, Nicolas A. ^{[1
]}

Lin, James ^{[4
]}

Smiddy, William E. ^{[1
]}

机构：

[1] Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Miller Sch Med, Miami, FL USA

[2] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA

[3] Boston Childrens Hosp, Dept Ophthalmol, Boston, MA USA

[4] Vitreoretinal Consultants New York, Dept Ophthalmol, New York, NY USA

来源：

OPHTHALMOLOGY RETINA | 2022年 / 6卷 / 11期

关键词：

Age-related macular degeneration; Cost analysis; Intravitreal injection; Ranibizumab;

D O I：

10.1016/j.oret.2022.05.021

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

[No abstract available]

引用

页码：1105 / 1106

页数：2

共 7 条

[1] Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials [J].

Heier, Jeffrey S. ;

Khanani, Arshad M. ;

Ruiz, Carlos Quezada ;

Basu, Karen ;

Ferrone, Philip J. ;

Brittain, Christopher ;

Figueroa, Marta S. ;

Lin, Hugh ;

Holz, Frank G. ;

Patel, Vaibhavi ;

Lai, Timothy Y. Y. ;

Silverman, David ;

Regillo, Carl ;

Swaminathan, Balakumar ;

Viola, Francesco ;

Cheung, Chui Ming Gemmy ;

Wong, Tien Y. .

LANCET, 2022, 399 (10326) :729-740

[2] Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration [J].

Holekamp, Nancy M. ;

Campochiaro, Peter A. ;

Chang, Margaret A. ;

Miller, Daniel ;

Pieramici, Dante ;

Adamis, Anthony P. ;

Brittain, Christopher ;

Evans, Erica ;

Kaufman, Derrick ;

Maass, Katie F. ;

Patel, Shienal ;

Ranade, Shrirang ;

Singh, Natasha ;

Barteselli, Giulio ;

Regillo, Carl .

OPHTHALMOLOGY, 2022, 129 (03) :295-307

[3] Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial [J].

Kertes, Peter J. ;

Galic, Ivan J. ;

Greve, Mark ;

Williams, Geoff ;

Baker, Jason ;

Lahaie, Marcel ;

Sheidow, Tom .

JAMA OPHTHALMOLOGY, 2020, 138 (03) :244-250

[4] Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group [J].

Martin, Daniel F. ;

Maguire, Maureen G. ;

Ying, Gui-shuang ;

Grunwald, Juan E. ;

Fine, Stuart L. ;

Jaffe, Glenn J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (20) :1897-1908

[5] Ranibizumab for neovascular age-related macular degeneration [J].

Rosenfeld, Philip J. ;

Brown, David M. ;

Heier, Jeffrey S. ;

Boyer, David S. ;

Kaiser, Peter K. ;

Chung, Carol Y. ;

Kim, Robert Y. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1419-1431

[6] Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study [J].

Ruiz-Moreno, Jose M. ;

Arias, Luis ;

Abraldes, Maximino J. ;

Montero, Javier ;

Udaondo, Patricia .

INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (10) :3427-3436

[7]

Wykoff CC, 2 YEAR OUTCOMES PHAS

← 1 →